Anna F. Farago, MD, PhD

Articles

Dr. Farago on Frontline Immunotherapy Versus Maintenance Immunotherapy in SCLC

September 6th 2019

Anna F. Farago, MD, PhD, medical oncologist at the Center for Thoracic Cancers at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses the use of frontline immunotherapy versus maintenance immunotherapy in patients with small cell lung cancer (SCLC).

Dr. Farago on Effectiveness of Single-Agent Lurbinectedin in SCLC

September 4th 2019

Anna F. Farago, MD, PhD, assistant professor of medicine at Harvard Medical School, discusses the phase II trial results using the marine-based drug lurbinectedin as a single agent treatment inpatients with small cell lung cancer.

Dr. Farago on Eligibility Criteria for Frontline Immunotherapy in SCLC

August 7th 2019

Anna F. Farago, MD, PhD, attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses patient eligibility criteria for frontline immunotherapy in small cell lung cancer (SCLC).

Dr. Farago on the FDA Approval of Pembrolizumab for Lower PD-1 Cutoff NSCLC

April 12th 2019

Anna F. Farago, MD, PhD, assistant professor of medicine at Harvard Medical School, discusses the FDA approval of single-agent pembrolizumab for the frontline treatment of patients with stage III non–small cell lung cancer, who are ineligible for surgery or definitive chemoradiation, or metastatic NSCLC, with a PD-L1 expression (tumor proportion score) level of ≥1% and do not harbor EGFR or ALK aberrations.

x